'UK first' equipment to benefit University's cancer research

Cancer research at Nottingham Trent University has received a major boost, with the institution becoming the first UK recipient of new equipment able to identify molecules which play a crucial role in the disease.

It will be an invaluable tool in allowing us to quantify large numbers of proteins simultaneously in clinical samples.

Dr David Boocock, Nottingham Trent University

Cancer research at Nottingham Trent University has received a major boost, with the institution becoming the first UK recipient of new equipment able to identify molecules which play a crucial role in the disease.

The University's John van Geest Cancer Research Centre has purchased a next generation mass spectrometer to support its work in improving the early diagnosis and treatment of breast and prostate cancers.

The instrument, only the second in Europe, is used to weigh molecules, enabling scientists to identify proteins, or parts of proteins, which are important to cancer. These 'biomarkers' could then be used to help with early detection of cancer, or be used as potential targets for a new cancer vaccine.

"This will take our cancer biomarker discovery ability to the next level and will be hugely beneficial in terms of the way we plan and carry out research," said Dr David Boocock, Group Leader of the Clinical Proteomics group in the University's John van Geest Cancer Research Centre.

He said: "It will be an invaluable tool in allowing us to quantify large numbers of proteins simultaneously in clinical samples. We will be able to see each sample in much more detail than was previously possible."

The instrument, an AB SCIEX TripleTof ® 6600, is worth more than £450,000 and is being funded by the Healthcare and Bioscience iNet – an ERDF funded initiative managed by Medilink East Midlands – and the John van Geest Cancer Research Centre.

It replaces the TripleTOF® 5600+ system, which the research centre previously used.

  • Notes for editors

    Press enquiries please contact Dave Rogers, Head of Communications, on telephone +44 (0)115 848 8782, or via email.

    The new TripleTOF® 6600 System with SWATH™ Acquisition 2.0 Captures Every Detectable Protein and Peptide in Every Run for Deep Insights into the Proteome. View more information.

    Nottingham Trent University’s John van Geest Cancer Research Centre is a unique purpose-built scientific facility. Its aim is to save lives and speed recovery by improving the early diagnosis and treatment of cancer.

    The centre focuses on two key approaches to the treatment of patients with cancer:

    • Improving the diagnosis and management of breast and prostate cancers
    • Developing effective vaccines and immunotherapies that will significantly improve the survival rates and quality of life for cancer sufferers.

    Previous research at the centre identified HAGE as a protein expressed in several types of human tumours, important in the progression of cancer, as a potential therapeutic target and, as shown here, a biomarker in breast cancer associating with aggressive disease, but also predictive of the outcome of current therapies.

    Visit the John van Geest Cancer Research Centre website to find out more about its work, or to make a donation towards its vital scientific research.

    About the Healthcare and Bioscience iNet

    The Healthcare and Bioscience iNet is an initiative, which is part-financed by the European Regional Development Fund (ERDF), and delivered by Medilink East Midlands. A key aim of the iNet is to provide a sector-specific focus that enables organisations to exchange knowledge, form collaborations to develop new technologies, processes, products and services in order to build a healthy economy.

    About ERDF in the East Midlands

    The Healthcare & Bioscience iNet project is part financed by the Structural Funds for the East Midlands Region of the European Regional Development Fund Programme 2007 to 2013. The Department for Communities and Local Government is the managing authority for the European Regional Development Fund Programme, which is one of the funds established by the European Commission to help local areas stimulate their economic development by investing in projects which will support local businesses and create jobs. For more information visit GOV.UK.

'UK first' equipment to benefit University's cancer research

Published on 24 October 2014
  • Category: Press office; Research; School of Science and Technology

Still need help?

+44 (0)115 941 8418